8-K: TC BioPharm Secures $3.1 Million Through Warrant Exercise, Issues New Warrants

TC BioPharm has entered into an agreement for the immediate exercise of existing warrants, generating approximately $3.1 million in gross proceeds and issuing new warrants for future share purchases.

Summary

• TC BioPharm has secured a commitment for the immediate exercise of existing warrants, which are expected to generate gross proceeds of approximately $3.1 million.
• The existing warrants, issued in December 2023, had an exercise price of $1.5814 per ADS and a five-year term.
• In exchange for the immediate exercise and a payment of $0.125 per new warrant, the company will issue new warrants to purchase up to 3,500,000 ADSs.
• The new warrants have an exercise price of $1.175 per ADS and are exercisable for 42 months from the issuance date.
• The company intends to use the net proceeds to support an upcoming clinical trial for acute myeloid leukemia and for general operating expenses and working capital.
• The closing of the transaction is expected to occur on or about May 8, 2024, subject to customary closing conditions.

Sentiment

Score: 7

Explanation: The document indicates a positive development for the company as it secures funding for its clinical trial. However, the use of warrants and the associated restrictions on future issuances introduce some uncertainty.

Positives

• The company has successfully secured $3.1 million in funding through the exercise of existing warrants.
• The new warrants provide a potential future source of capital for the company.
• The funds will be used to support a clinical trial, which is a key step in the company's development.
• The new warrants have a lower exercise price than the existing warrants, which may be attractive to investors.

Negatives

• The new warrants are being offered in a private placement and are not registered under the Securities Act.
• The company has agreed to pay placement agent fees and expenses, which will reduce the net proceeds from the offering.
• The company has agreed to certain restrictions on future equity issuances and variable rate transactions.

Risks

• The new warrants are not registered and may have limited liquidity.
• The company is subject to certain restrictions on future equity issuances and variable rate transactions.
• The company's ability to successfully complete its clinical trial is subject to various risks and uncertainties.
• The company may need to raise additional capital in the future to fund its operations.

Future Outlook

The company intends to use the net proceeds from this offering to support its upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, and for continuing operating expenses and working capital.

Management Comments

• TC BioPharm is pleased to offer to you (Holder, you or similar terminology) the opportunity to receive new warrants to purchase ordinary shares, par value 0.0001 per share, of the Company (the Ordinary Shares) represented by American Depositary Shares of the Company (the ADSs) in consideration for you exercising for cash all of the warrants to purchase Ordinary Shares represented by ADSs held by you (Existing Warrants) as set forth on your signature page hereto.

Industry Context

This announcement is relevant to the biotechnology industry, particularly companies focused on developing novel cancer therapies. The use of warrants to raise capital is a common practice in this sector, especially for clinical-stage companies.

Comparison to Industry Standards

• The use of warrants for fundraising is a common practice among clinical-stage biotech companies, similar to companies like Celldex Therapeutics and Adaptimmune Therapeutics.
• The terms of the warrants, including the exercise price and duration, are within the typical range for such instruments in the biotech sector.
• The size of the capital raise, $3.1 million, is relatively small compared to larger biotech companies, but is typical for a company at TC BioPharm's stage of development.
• The focus on funding a specific clinical trial is a common use of funds raised through warrant exercises, similar to companies like Bellicum Pharmaceuticals.

Stakeholder Impact

• Shareholders will see a dilution of their ownership due to the issuance of new warrants.
• The company's employees will benefit from the funding of the clinical trial and the company's continued operations.
• The company's customers (patients) may benefit from the development of new cancer therapies.
• The company's suppliers and creditors will benefit from the company's continued operations.

Next Steps

• The company will close the warrant exercise transaction on or about May 8, 2024.
• The company will file a registration statement for the resale of the new warrant ADSs within 30 days of the closing date.
• The company will use the net proceeds to support its upcoming clinical trial and for working capital.

Key Dates

Keywords

warrants, capital raise, clinical trial, acute myeloid leukemia, ADS, placement agent, biopharmaceutical, gamma-delta T cell therapy, private placement